Vertex to Acquire Crinetics Pharmaceuticals for USD 10 Billion

Last edition

Vertex to Acquire Crinetics Pharmaceuticals for USD 10 Billion

Vertex Pharmaceuticals Incorporated has entered into a definitive agreement to acquire Crinetics Pharmaceuticals, Inc. in an all-cash transaction valued at approximately USD 10 billion, strengthening its presence in rare endocrine disorders and expanding its portfolio beyond its core cystic fibrosis business.

Under the terms of the agreement, Vertex will acquire all outstanding shares of Crinetics for USD 85 per share in cash, representing a net transaction value of approximately USD 8.8 billion after accounting for estimated cash acquired. The deal has been unanimously approved by the boards of both companies and is expected to close in the third quarter of 2026, subject to regulatory approvals and approval by Crinetics' shareholders.

The acquisition brings to Vertex PALSONIFY (paltusotine), the first and only once-daily oral treatment approved for adults with acromegaly, a rare hormonal disorder caused by excess growth hormone secretion from pituitary tumours. The therapy received approval from the US Food and Drug Administration (FDA) in September 2025 and has since secured approval from the European Medicines Agency (EMA), while regulatory reviews continue in other global markets.

According to the companies, PALSONIFY has demonstrated strong early commercial momentum since its launch, supported by increasing physician adoption, expanding reimbursement coverage, and demand across both treatment-naïve and previously treated patient populations.

Vertex will also gain access to Crinetics' late-stage pipeline candidate, atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in Phase 3 clinical development for congenital adrenal hyperplasia (CAH). The investigational therapy has shown promising Phase 2 results, enabling patients to achieve near-normal androgen levels while using physiologic doses of glucocorticoids, potentially addressing a significant unmet need in the treatment of the rare genetic disorder.

Reshma Kewalramani, MD, CEO and President of Vertex, said, “Crinetics is an excellent strategic fit for Vertex, with its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines that could deliver transformative benefit to patients. We believe Vertex can build on the strong momentum of the PALSONIFY launch by applying our experience in commercialising medicines for rare genetic diseases.”

“Nearly 18 years ago, we founded Crinetics with a clear goal of transforming the lives of patients living with endocrine-related diseases. Today marks a historic milestone as we embark on this next chapter with Vertex. This partnership is anchored by a mutual commitment to science and a shared vision for delivering innovative treatments to patient communities that have long been underserved. Vertex’s global infrastructure and commercial footprint will amplify the reach of our science and allow us to maximise the impact of PALSONIFY, atumelnant, and our pipeline,” said Scott Struthers, PhD, Founder and CEO of Crinetics Pharmaceuticals.

From a financial perspective, Vertex expects the acquisition to contribute immediately to revenue growth through the continued rollout of PALSONIFY. Longer term, the company believes atumelnant has multi-billion-dollar commercial potential in CAH, with additional opportunities in Cushing's syndrome. At peak, the combined assets are projected to generate more than USD 5 billion in annual revenue, supporting Vertex's strategy of sustained double-digit revenue growth. The company expects the acquisition to become accretive to non-GAAP operating income by 2029.

Vertex plans to finance the acquisition through a combination of existing cash reserves and debt financing, supported by USD 4.5 billion in fully committed bridge financing from Bank of America and Morgan Stanley.

Morgan Stanley and Lazard are serving as financial advisors to Vertex, while J.P. Morgan Securities and Leerink Partners are advising Crinetics on the transaction.

Read more on:
Crinetics Pharmaceuticals European Medicines Agency US Food and Drug Administration USFDA Vertex PALSONIFY Vertex Pharmaceuticals

More news about: global pharma | Published by Abha | July - 08 - 2026

Last news about this category